Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face ...
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast ...
Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...
Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength ...
Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.